PDF(Pubmed)
Abstract：
The aim of our meta-analysis is to analyze data available in the literature regarding a possible prognostic value of the albumin to globulin ratio (AGR) in prostate cancer (PC) patients. We distinguished our analysis in terms of PC staging, histologic aggressiveness, and risk of progression after treatments. A literature search process was performed (“prostatic cancer”, “albumin”, “globulin”, “albumin to globulin ratio”) following the PRISMA guidelines. In our meta-analysis, the pooled Event Rate (ER) estimate for each group of interest was calculated using a random effect model. Cases were distinguished in Low and High AGR groups based on an optimal cut-off value defined at ROC analysis. Four clinical trials were enclosed (sample size range from 214 to 6041 cases). The pooled Risk Difference for a non-organ confined PC between High AGR and Low AGR cases was −0.05 (95%CI: −0.12−0.01) with a very low rate of heterogeneity (I2 < 0.15%; p = 0.43) among studies (test of group differences p = 0.21). In non-metastatic PC cases, the pooled Risk Difference for biochemical progression (BCP) between High AGR and Low AGR cases was −0.05 (95%CI: −0.12−0.01) (I2 = 0.01%; p = 0.69) (test of group differences p = 0.12). In metastatic PC cases, AGR showed an independent significant (p < 0.01) predictive value either in terms of progression free survival (PFS) (Odds Ratio (OR): 0.642 (0.430−0.957)) or cancer specific survival (CSS) (OR: 0.412 (0.259−0.654)). Our meta-analysis showed homogeneous results supporting no significant predictive values for AGR in terms of staging, grading and biochemical progression in non-metastatic PC.
摘要：
我们的荟萃分析的目的是分析文献中有关前列腺癌（PC）患者白蛋白与球蛋白比率（AGR）的可能预后价值的数据。我们在PC分期方面区分了我们的分析，组织学侵袭性，和治疗后进展的风险。进行了文献检索过程(“前列腺癌”，“白蛋白”，\"球蛋白\",“白蛋白与球蛋白之比”)遵循PRISMA指南。在我们的荟萃分析中，使用随机效应模型计算每个目标组的合并事件发生率(ER)估计值.基于在ROC分析中定义的最佳截止值,在低AGR和高AGR组中区分病例。附上了四项临床试验（样本量为214至6041例）。高AGR和低AGR病例之间非器官受限PC的合并风险差异为-0.05（95CI：-0.12-0.01），异质性率非常低（I2＆lt;0.15％；p=0.43）研究（组间差异检验p=0.21）。在非转移性PC病例中，高AGR和低AGR病例的合并生化进展风险(BCP)差异为-0.05(95CI:-0.12-0.01)(I2=0.01%;p=0.69)(组间差异检验p=0.12).在转移性PC病例中，AGR在无进展生存期（PFS）（赔率比（OR）：0.642（0.430-0.957））或癌症特异性生存期（CSS）（OR：0.412（0.259-0.654））方面显示出独立的显着（p<0.01）预测值。我们的荟萃分析显示，同质结果支持AGR在分期方面没有显著的预测值，非转移性PC的分级和生化进展。
